ISCHEMIA: Early intervention vs. conservative therapy can improve angina symptoms, quality of life for patients with SIHD and angina

Researchers in “Results for the ISCHEMIA Trials: To Intervene or Not To Intervene” Late-Breaking Science session during Scientific Sessions found Initial invasive therapy compared to optimal medical therapy in patients with stable ischemia heart disease and moderate-severe ischemia did not reduce the risk for cardiovascular events.

New agents, targets becoming part of lipid management

High-dose statins, ezetimibe and PCSK inhibition are not the final word in lowering lipids. During a Late-Breaking Science session last month, investigators revealed new findings and approaches to manage lipids.

Trials’ results suggest outside-the-box approaches to reduce CVD risk

Investigators in four trials revealed surprising findings on novel approaches to reduce CVD risk during their Late-Breaking Science session at Scientific Sessions. The glucose-lowering drug dapagliflozin may benefit heart failure patients without diabetes.

Results inform management of severe aortic stenosis

Researchers in Late-Breaking Science sessions during Scientific Sessions presented the latest findings on optimal timing of surgery for asymptomatic severe aortic stenosis, best prosthetic valve design and whether anticoagulation is efficacious and safe for patients after TAVR without indication for anticoagulation.

Trials may change outlook on interventional management for ACS

In a Late-Breaking Clinical Trial session during Scientific Sessions, investigators exploring interventional management for acute coronary syndrome patients found Ticagrelor alone was as effective as ticagrelor plus aspirin in reducing ischemic events while reducing bleeding risk in a subgroup of high-risk patients after percutaneous coronary intervention for ACS.

Drug combination may reduce CV mortality in HF patients across the ejection fraction spectrum

Researchers in Late-Breaking Science sessions during Scientific Sessions presented the pooled PARAGON-HF and PARADIGM-HF analysis and the latest results on gender differences and response to treatment in heart failure patients with preserved ejection fraction, a drug that improves exercise performance with Fontan circulation and how older HF patients tolerated dapagliflozin and patients’ reported quality of life